The relationship between apolipoprotein (apo) E and vascular disease has been the subject of a considerable amount of research. However, this relationship is far from clearly defined. This deficiency appears to be due to a multitude of factors. Among these are differences in ethnicity, age (and possibly gender), diagnostic criteria, and environmental factors (eg, diet and smoking) that have contributed to the contradictory findings. Several diseases and their treatment may also influence this relationship. There are also documented interactions between apo E genotypes and other genes or vascular risk factors. One possible clinically relevant application of identifying the apo E genotype could be to assess the response to a particular drug treatment. It may also be that apo E polymorphism will become a good predictor of vascular death (eg, from myocardial infarction or stroke) rather than an indicator of the risk of developing vascular disease but without an acute ischemic event. More research is required to define the place of apo E genotyping in the management of vascular disease in its various forms. Whatever the future brings, the evaluation of apo E genotypes will need to be rapid, cheap, and technically undemanding before this investigation becomes widely available and clinically relevant.
Get full access to this article
View all access options for this article.
References
1.
Saunders AM, Strittmatter WJ, Schmechel D., et al: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology43:1467-1472, 1993.
2.
Myhre A., Tysnes OB: Etiology and genetics of Alzheimer disease. Tidsskr Nor Laegeforen122:50-53, 2002.
3.
Schächter F. , Faure-Delanef L., Guénot F., et al: Genetic associations with human longevity at the apo E and ACE loci. Nat Genet6:29-32, 1994.
4.
Jovone T., Kervinen K., Kairaluoma MI, et al: Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology104:1806-1813, 1993.
5.
Van Erpecum KJ, Carey MC: Apolipoprotein E4: Another risk factor for cholesterol gallstone formation ? Gastroenterology111:1764-1767, 1996.
6.
Kervinen K., Sodervik H., Makela J., et al: Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? Gastroenterology110:1785-1790, 1996.
7.
Zunarelli E. , Nicoll JA, Migaldi M., et al: Apolipoprotein E polymorphism and breast carcinoma: Correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat63:193-198, 2000.
8.
Zunarelli E. , Nicoll JA, Trentini GP: Apolipoprotein E polymorphism and central nervous system tumors: Correlation with cell proliferation indices and clinical outcome. Clin Neuropathol19:1-6, 2000.
9.
Carlin C., Murray L., Graham D., et al: Involvement of apolipoprotein E in multiple sclerosis: Absence of remyelination associated with possession of the Apo E epsilon2 allele. J Neuropathol Exp Neurol59:361-367, 2000.
10.
McCarron MO , Nicoll JA: Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann NY Acad Sci903:176-179, 2000.
11.
Nicoll Jar, McCarron MO, Weir CJ, et al: Apolipoprotein E polymorphism and in-hospital mortality following intracerebral hemorrhage. Neurology54(suppl 3):A386-A387, 2000.
12.
Grocott HP, Newman MF, El-Moalem H., et al: Apolipoprotein E genotype differentially influences the proinflammatory and antiinflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg122:622-623, 2001.
13.
Broderick J. , Lu M., Jackson C., et al: and the NINDS t-PA Stroke Study Group: Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol49:736-744, 2001.
14.
Ballantyne CM, Herd JA, Stein EA, et al: Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol36:1572-1578, 2000.
15.
Corella D., Tucker K., Lahoz C., et al: Alcohol drinking determines the effect of the apo E locus on LDL-cholesterol concentrations in men: The Framingham Offspring Study. Am J Clin Nutr73:736-745, 2001.
16.
Rall SC, Weisgraber KH, Mahley RW: Human apolipoprotein E: The complete amino acid sequence. J Biol Chem257:4171-4178, 1982 .
17.
Taira K., Bujo H., Hirayama S., et al: LR11, a mosaic LDL receptor family member, mediates the uptake of Apo E-rich lipoproteins in vitro. Arterioscler Thromb Vasc Biol21:1501-1506, 2001.
18.
Kamboh MI, Aston CE, Ferrell RE, et al: Impact of apolipoprotein E polymorphism in determining interindividual variation in total cholesterol and low-density lipoprotein cholesterol in Hispanics and non-Hispanic whites. Atherosclerosis98:201-211, 1993.
19.
Xhignesse M. , Lussier-Cacan S., Sing CF, et al: Influence of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb11:1100-1110, 1991 .
20.
Paik YK, Chang DJ, Reardon CA, et al: Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA82:3445-3449, 1985.
21.
Utermann G. , Albrecht G., Steinmetz A.: Polymorphism of apolipoprotein E. Clin Genet14:351-358, 1978.
22.
Hoffmann MM , Scharnagl H., Koster W., et al: Apolipoprotein E., Baden (Arg(180 → Cys). A new apolipoprotein E variant associated with hypertriglyceridemia . Clin Chim Acta303:41-48, 2001.
23.
Gomes-Coronado D., Alvarez JJ, Entrala A., et al: Apolipoprotein E polymorphism in men and women from a Spanish population: Allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis147:167-176, 1999.
24.
Yoshida H., Hasty AH, Major AS, et al: Isoform-specific effects of apolipoprotein E on atherosclerosis . Gene transduction studies in mice. Circulation104:2820-2825, 2001.
25.
Murphy MM, Vilella E., Ceruelo S., et al: The MTHFR C677T, apo E, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem48:372-375, 2002.
26.
Utermann G. , Hardewig A., Zimmer F.: Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet65:237-241, 1984.
27.
Utermann G. , Langenback U., Beisigel U., et al: Genetics of the apolipoprotein E system in man. Am J Hum Genet32:339-347, 1980.
28.
Kuusi T., Nieminen MS, Ehnholm C., et al: Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients . Arteriosclerosis9:237-241, 1989.
29.
Hixson JE: Apolipoprotein E polymorphisms affect atherosclerosis in young males: Pathobiological determinants of atherosclerosis in youth (PDAY) research group . Arterioscler Thromb11:1237-1244, 1991 .
30.
van Bockxmeer FM, Mamotte CD: Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet340:879-880, 1992.
31.
Tiret L., de Knijff P., Menzel HJ, et al: Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS study. European Atherosclerosis Research Study. Arterioscler Thromb14:1617-1624, 1994.
32.
Stengard JH , Zerba KE, Pekkanen J., et al: Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation91:265-269, 1995.
33.
Lahoz C., Schaefer E., Cupples LA, et al: Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis154: 529-537, 2001.
34.
Cumming AM, Robertson FW: Polymorphism at the apoprotein-E locus in relation to risk of coronary disease . Clin Genet25:310-313, 1984.
35.
Eichner JE, Kuller LH, Orchard TJ, et al: Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol71:160-165, 1993.
36.
Luc G., Bard JM, Arveiler D., et al: Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb14:1412-1419, 1994.
37.
Brscic E., Bergerone S., Gagnor A., et al: Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide syntheses, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J139:979-984, 2000.
38.
Kolovou G., Yiannakouris N., Malakos J., et al: Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients. Curr Med Res Opin18:118-124, 2002.
39.
Kolovou G., Malakos JS, Hatzaki A., et al: Apolipoprotein E but not angiotensin-converting enzyme polymorphism is associated with myocardial infarction. J Am Coll Cardiol29:82A, 1997.
40.
Hatzaki A., Kolovou G., Hatzivassiliou M., et al: Is there an allelic effect of apolipoprotein E gene polymorphism on plasma lipid parameters in Greek patients with myocardial infarction? Eur Heart J18(suppl):64, 1997.
41.
De Knijff P. , Jansen H., Lie KI, et al: Apolipoprotein E4 and coronary artery disease. Lancet340:1351, 1992 .
42.
Scuteri A., Bos A., Zonderman A., et al: Is the apoE4 allele an independent predictor of coronary events ? Am J Med110:28-32, 2001.
43.
Stengard JH , Weiss KM, Sing CF: An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet103:234-241, 1998.
44.
McCarron MO , Delong D., Alberts MJ: Apo E genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis. Neurology53:1308-1311, 1999.
45.
MacLeod MJ, De Lange RP, Breen G., et al: Lack of association between apolipoprotein E genotype and ischaemic stroke and Scottish population. Eur J Clin Invest31:570-573, 2001.
46.
Couderc R., Mahieux F., Bailleul S., et al: Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: A case-control study. Stroke24:661-664, 1993.
47.
Slooter AJ, Tang MX, van Duijn CM, et al: Apolipoprotein E epsilon4 and the risk of dementia with stroke: A population-based investigation. JAMA277:818-821, 1997.
48.
Margaglione M., Seripa D., Gravina C., et al: Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: An Italian case-control study. Stroke29:399-403, 1998.
49.
DeCarli C., Reed T., Miller BL, et al: Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke30:1548-1553, 1999.
50.
Mahley RW, Rall SC Jr: Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, ed. 7, ed. by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw-Hill, 1995, pp 1953-1980.
51.
De Beer F., Stalenhoef AF, Hoogerbrugge N., et al: Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158-ys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol22:294-299, 2002.
52.
Carmena R., Roy M., Roederer G., et al: Coexisting dysbetalipoproteinemia and familial hypercholesterolemia . Clinic and laboratory observations. Atherosclerosis148:113-124, 2000.
53.
Wilson PW, Schaefer EJ, Larson MG, et al: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis . Arterioscler Thromb Vasc Biol16: 1250-1255, 1996.
54.
Kalix B., Meynet MC, Garin MC, et al: The apolipoprotein epsilon2 allele and the severity of coronary artery disease in Type 2 diabetic patients. Diabet Med18:445-450, 2001.
55.
Sing CF, Davingnon J.: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet37:268-285, 1985.
56.
Ehnholm C., Lukka M., Kuusi T., et al: Apolipoprotein E polymorphism in the Finnish population: Gene frequencies and relation to lipoprotein concentrations. J Lipid Res27:227-235, 1986.
57.
Dallongeville J., Lussier-Cacan S., Davignon J.: Modulation of plasma triglyceride levels by apo E phenotype: A meta-analysis. J Lipid Res33:447-454, 1992.
58.
Deiana L., Pes GM, Carru C., et al: Lack of influence of apolipoprotein E4 on lipoprotein levels in the island population of Sardinia. Eur J Clin Invest28:290-294, 1998.
59.
Aguilar CA, Talavera G., Ordovas JM, et al: The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a Native American population following its traditional lifestyle . Atherosclerosis142:409-414, 1999.
60.
Attila G., Acarturk E., Eskandari G., et al: Effects of apolipoprotein E genotypes and other risk factors on the development of coronary artery disease in Southern Turkey. Clin Chim Acta312:191-196, 2001.
61.
Lehtimaki T. , Moilanen T., Aalto-Setala K., et al: Association of apolipoprotein E and B polymorphisms with serum lipids. Ann Med23:657-662, 1991.
62.
Davignon J., Cohn JS, Mabile L., et al: Apolipoprotein E and atherosclerosis: Insight from animal and human studies. Clin Chim Acta286:115-143, 1999.
63.
Ilveskoski E., Jarkvinen O., Sisto T., et al: Apolipoprotein E polymorphism and atherosclerosis: Association of the epsilon4 allele with defects in the internal elastic lamina. Atherosclerosis153:155-160, 2000.
64.
Dreon DM, Peroutkal SJ: Medical utility of apo E allele determination in assessing the need for antioxidant therapy. Med Hypotheses56:357-359, 2001.
65.
Lynch JR, Morgan D., Mance J., et al: Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol114:107-113, 2001.
66.
Stannard AK , Riddell DR, Sacre SM, et al: Cell-derived apolipoprotein E (Apo E) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem276:46011-46016, 2001.
67.
Calara F., Silvestre M., Casanada F., et al: Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol195:257-263, 2001.
68.
Libby P.: Molecular bases of the acute coronary syndromes. Circulation91:2844-2850, 1996.
69.
Faber B., Cleutjens K., Niessen R., et al: Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res89:547-554, 2001.
70.
Dallongeville J.: Apolipoprotein E.: Proprietes physiologiques, polymorphisme et atherosclerose. Sang Thrombose Vaisseaux5:707-717, 1993.
71.
James RW, Boemi MG, Giansanti R., et al: Under-expression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb13:1456-1459, 1993.
72.
Bailleul S. , Couderc R., Landais V., et al: Direct phenotyping of human apolipoprotein E in plasma: Application to population frequency distribution in Paris (France) . Hum Hered43:159-165, 1993.
73.
Davignon J. , Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis . Atherosclerosis8:1-21, 1988.
74.
Eggertsen G. , Tegelman R., Ericsson S., et al: Apolipoprotein E polymorphism in a healthy Swedish population : Variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem39:2125-2129, 1993.
75.
Gerdes LU, Jeune B., Ranberg KA, et al: Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: Apolipoprotein E gene is a "frailty gene," not a "longevity gene." Genet Epidemiol19:202-210, 2000.
76.
Nassar BA, Dunn J., Title LM, et al: Relation of genetic polymorphism of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B-100, and glycoprotein IIIa and early onset coronary heart disease. Clin Biochem32:275-282, 1999.
77.
Frikke-Schmidt R., Tybjaerg-Hansen A., Steffensen R., et al: Apolipoprotein E genotype:epsilon 32 women are protected while epsilon 43 and epsilon 44 men are susceptible to ischemic heart disease. The Copenhagen City Heart Study . J Am Coll Cardiol35:1192-1199, 2000 .
78.
Stankovic S. , Glisic S., Alavanatic D.: The effect of a gender difference in the apolipoprotein E gene DNA polymorphism on serum lipid levels in a Serbian healthy population. Clin Chem Lab Med38 :539-544, 2000.
79.
Wilson Pwf, Myers RH, Larson MG, et al: Apolipoprotein E alleles, dyslipidemias and coronary heart disease: The Framingham Offspring Study. JAMA272:1666-1671, 1994.
80.
Oh JY, Barrett-Connor E; Rancho Bernardo Study Group. Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes : The Rancho Bernardo Study. Clin Genet60:132-137, 2001.
81.
Newman MF, Laskowitz DT, White WD, et al: Apolipoprotein E polymorphism and age at first coronary bypass graft. Anesth Analg92:824-829, 2001.
82.
van Bockxmeer FM, Mamotte Cds, Gibbons FA, et al: Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty . Circulation92:2066-2071, 1995 .
83.
Vauhkonen I. , Niskanen L., Ryynanen M., et al: Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects . Diabet Med14:48-56, 1997.
84.
Papadakis JA , Milionis HJ, Press M., et al: Treating dyslipidaemia in non-insulin dependent diabetes mellitus—a special reference to statins . J Diabetes Complic15:211-226, 2001.
85.
Ha SK, Park HS, Kim KW, et al: Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant14:2144-2149, 1999 .
86.
Soedamah-Muthu SS, Colhoun HM, Taskinen MR, et al: EURODIAB IDDM Complications Study Group. Diabetologia43:1353-1359, 2000 .
87.
Marcais C., Bernard S., Merlin M., et al: Severe hypertriglyceridaemia in type II diabetes: Involvement of apo C-III Sst-I polymorphism, LPL mutations and apo E3 deficiency. Diabetologia43:1346-1352, 2000 .
88.
Peng DQ, Zhao SP, Wang JL: Lipoprotein (a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk6:1-6, 1999.
89.
Marin DB, Breuer B., Marin ML, et al: The relationship between apolipoprotein E, dementia, and vascular illness. Atherosclerosis140:173-180, 1998.
90.
Zhu L., Fratiglioni L., Guo Z., et al: Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke31:53-60, 2000.
91.
Ferrucci L., Guralnik JM, Pahor M., et al: Apolipoprotein E ε2 allele and risk of stroke in the older population. Stroke28:2410-2416, 1997 .
92.
Catto AJ, McCormack LJ, Mansfield MW, et al: Apolipoprotein E polymorphism in cerebrovascular disease. Acta Neurol Scand101:399-404, 2000.
93.
Pedro-Botet J., Senti M., Nogues X., et al: Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein (a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke23:1556-1562, 1992.
94.
Lynch JR, Pineda JA, Morgan D., et al: Apolipoprotein E affects the central nervous system response to injury and development of cerebral edema. Ann Neurol51:113-117, 2002.
95.
Skoog I., Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord13(suppl 3):106-114, 1999.
96.
Hillen T., Nieczaj R., Munzberg H., et al: Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: The Berlin ageing study. J Intern Med247:679-688, 2000.
97.
Ilveskoski E. , Loimaala A., Mercuri MF, et al: Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample of middle-aged men . Atherosclerosis153:147-153, 2000.
98.
Horesji B., Spacil J., Ceska R., et al: The independent correlation of the impact of lipoprotein (a) levels and apolipoprotein E polymorphism on carotid artery intima thickness . Int Angiol19:331-336, 2000.
99.
Slooter AJ, Bots ML, Havekes LM, et al: Apolipoprotein E and carotid artery atherosclerosis: The Rotterdam study. Stroke32:1947-1952, 2001 .
100.
Rizos E., Mikhailidis DP: Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res52:199-207, 2001.
101.
Mikhailidis DP, Wierzbicki AS (editorial comment): The GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study. Curr Med Res Opin2002; in press.
102.
Ilveskoski E., Perola M., Lehtimaki T., et al: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: An autopsy study. Circulation100:608-613, 1999.
103.
Guz G., Nurhan Ozdemir F., Sezer S., et al: Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis36:826-836, 2000.
104.
Elisaf M., Mikhailidis DP: Statins and renal function. Angiology2002 ; in press.
105.
Resnick HE , Rodriguez B., Havlik R., et al: Apo E genotype, diabetes, and peripheral arterial disease in older men: The Honolulu Asia-aging study. Genet Epidemiol19:52-63, 2000.
106.
Milionis HJ , Rizos E., Mikhailidis DP: Smoking diminishes the beneficial effect of statins: Observations from the landmark trials. Angiology52:575-587, 2001.
107.
Senti M., Nogues X., Pedro-Botet J., et al: Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation85:30-36, 1992.
108.
Gerdes LU, Gerdes C., Kervinen K., et al: The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study. Circulation101:1366-1371, 2000.
109.
Dallongeville J., Tiret L., Visvikis S., et al: The effect of apo E phenotype and plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: The EARS II study. European Atherosclerosis Research Study. Atherosclerosis145:381-388, 1999.
110.
Pedro-Botet J., Schaefer EJ, Bakker-Arkema RG, et al: Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender-specific manner. Atherosclerosis158:183-193, 2001.
111.
Carmena R. , Roederer G., Mailloux H., et al: The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism42:895-901, 1993.
112.
Nemeth A., Szakmary K., Kramer J., et al: Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Eur J Clin Chem Clin Biochem33:799-804, 1995.
113.
Frikke-Schmidt R. :Context dependent and invariant associations between apo E genotype and levels of lipoproteins and risk of ischemic heart disease: A review. Scand J Clin Lab Invest Suppl233:3-25, 2000.
114.
Liberopoulos E., Karabina SA, Tselepis A., et al: Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes ? Oncology62:115-120, 2002.
115.
Mikhailidis DP, Ganotakis ES, Georgoulias VA, et al: Tamoxifen-induced hypertriglyceridaemia: Seven case reports and suggestions for remedial action . Oncol Reports4:625-628, 1997.
116.
Tammi A., Ronnemaa T., Rask-Nissila L., et al: Apolipoprotein E phenotype regulates cholesterol absorption in healthy 13—month—old—children—The STRIP study. Pediatr Res50:688-691, 2001.
117.
Bernstein MS, Costanza MC, James RW, et al: Physical activity may modulate effects of Apo E genotype on lipid profile. Arterioscler Thromb Vasc Biol22:133-140, 2002.
118.
Hagberg JM, Ferrell RE, Katzel LI, et al: Apolipoprotein E genotype and exercise training-induced increases in plasma high-density lipoprotein (HDL)-and HDL2-cholesterol levels in overweight men. Metabolism48:943-945, 1999.
119.
Srinivasan SR , Ehnholm C., Elkasabany A., et al: Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: The Bogalusa Heart Study. Metabolism50:696-702, 2001.
120.
Szalai C., Czinner A., Csaszar A.: Influence of apolipoprotein E genotypes on serum lipid parameters in a biracial sample of children. Eur J Pediatr159:257-260, 2000.
121.
Lee JH, Tang MX, Schupf N., et al: Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. Am J Med Genet103:121-127, 2001.
122.
Kolovou GD , Daskalova DCh , Hatzivassiliou M., et al: The epsilon 2 and 4 alleles of apolipoprotein e and ischemic vascular events in the Greek population—implications for the interpretation of similar studies. Angiology2002; in press.
123.
Ibanez AM, Caamano MB, Fernandez Mvf, et al: Risk factors for cardiovascular and ischaemic heart disease in a Mediterranean country: Preliminary report of the Zaragoza study (ZACARIS-I) . Clin Drug Invest22:241-251, 2002.
124.
Papadakis JA, Mikhailidis DP, Winder AF: Lipids and stroke: Neglect of a useful preventive measure? Cardiovasc Res40:265-271, 1998.
125.
Athyros VG , Papageorgiou AA, Mercouris BR, et al: Treatment with Atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin18:220-228, 2002.
126.
Batalla A. , Alvarez R., Reguero JR, et al: Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphism in the risk for early myocardial infarction . Clin Chem46:1910-1915, 2000 .
127.
Larson IA, Ordovas JM, DeLuca C., et al: Association of apolipoprotein (Apo) E genotype with plasma apo E levels. Atherosclerosis148:327-335, 2000.
128.
Wu JH, Lo SK, Wen MS, et al: Characterization of apolipoprotein E genetic variations in Taiwanese: Association with coronary heart disease and plasma lipid levels. Hum Biol74:25-31, 2002.
129.
Paul A., Calleja L., Camps J., et al: The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci68:457-465, 2000.
130.
Djousse L. , Myers RH, Province MA, et al: Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung and Blood Institute Family Heart Study. Stroke33:1357-1361, 2002.
131.
Humphries SE, Talmud PJ, Hawe E., et al: Apolipoprotein ε4 and coronary artery disease in middle-aged men who smoke: A prospective study . Lancet358:115-119, 2001.
132.
Stengard JH , Kardia SL, Tervahauta M., et al: Utility of the predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65 to 84 years is dependent on context defined by Apo E genotype and area of residence. Clin Genet56:367-377, 1999.
133.
Shahmanesh M., Jaleel H., DeSilva Y., et al: Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype. Sex Transm Infec77:283-286, 2001.
134.
Fernandez-Miranda C., Cancelas P., de la Calle A., et al: Changes in phenotypes of apolipoprotein E and apolipoprotein (a) in liver transplant recipients. Clin Transplant11:325-327, 1997.
135.
Nikkila M. , Pitkajarvi T., Koivula T., et al: Women have a larger and less atherogenic low-density lipoprotein particle size than men . Atherosclerosis119:181-190, 1996.
136.
Chun S., Min WK, Kim JW, et al: Apolipoprotein E polymorphism and serum lipoprotein (a) concentrations in a Korean male population. Ann Clin Biochem38(Pt 2):129-134, 2001.
137.
Ritter MM, Gewitsch J., Richter WO, et al: Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein (a). Atherosclerosis131:243-248, 1997.
138.
Klausen IC , Gerdes LU, Hansen PS, et al: Effects of apo E gene polymorphism on Lp(a) concentrations depend on the size of apo(a): A study of 466 white men. J Mol Med74:685-690, 1996.
139.
Milionis HJ , Mikhailidis DP, Winder AF: Platelets and lipoprotein (a): A brief review of their role in the pathogenesis of atherothrombosis . Platelets10:277-284, 1999.
140.
Milionis HJ , Winder AF, Mikhailidis DP: Lp(a) and stroke. J Clin Pathol53:487-496, 2000.
141.
Prelevic GM , Kwong P., Byrne DJ, et al: A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril77: 945-951, 2002.
Jagroop IA , Mikhailidis DP: Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Hum Hypertens14:581-585, 2000.
144.
Jagroop IA , Mikhailidis DP: Doxazosin, an alphaladrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Human Hypertens15:203-207, 2001.
145.
Tonolo G., Melis MG, Formato M., et al: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest30:980-987, 2000.
146.
Borghi C., Veronesi M., Prandin MG, et al: Statins and blood pressure regulation. Curr Hypertens Rep3:281-288, 2001.
147.
Glorioso N., Troffa C., Filigheddu F., et al: Effect of the HMG-COA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension36:1281-1291, 1999 .
148.
Papadakis JA, Ganotakis ES, Jagroop IA, et al: Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am J Hypertens12:673-681, 1999.
149.
Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al: Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice. Intnl Angiol17:225-233, 1998.
150.
Wierzbicki AS, Mikhailidis DP: Beyond Ldl—C—the importance of raising HDL-C . Curr Med Res Opin18:36-44, 2002.
151.
Mikhailidis DP, Wierzbicki AS: HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin . Curr Med Res Opin16:139-146, 2000.
